Skip to main content

Table 4 Treatment response, mycological response, and crude mortality rates

From: Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

Outcome Micafungin Liposomal amphotericin B P valuea Total  
  Non-ICU (n = 127) ICU (n = 120) Non-ICU (n = 136) ICU (n = 110) Non-ICU ICU Non-ICU (n = 263) ICU (n = 230) P value
Overall treatment success 108 (85.0) 75 (62.5) 98 (72.1) 73 (66.4) 0.0113* 0.5828 206 (78.3) 148 (64.3) 0.0006*
Mycological response 109 (85.8) 88 (73.3) 106 (77.9) 79 (71.8) 0.1115 0.8825 215 (81.7) 167 (72.6) 0.2371
All-cause mortality at day 8 6 (4.7) 25 (20.8) 14 (10.3) 18 (16.4) 0.1057 0.4028 20 (7.6) 43 (18.7) 0.8935
All-cause mortality at day 30 25 (19.7) 46 (38.3) 32 (23.5) 38 (34.5) 0.4589 0.5852 57 (21.7) 84 (36.5) 0.0003*
  1. Data presented as n (%). ICU, intensive care unit. aMicafungin versus liposomal amphotericin B. *Statistically significant.